People with Ehlers-Danlos syndrome need to exercise particular caution with several widely prescribed drug classes, including non-steroidal anti-inflammatory drugs, systemic corticosteroids, certain local anesthetics, and some muscle relaxants. Because EDS involves structural defects in collagen and other connective-tissue proteins that leave the skin, ligaments, and blood vessels more fragile than normal, medications that further thin the blood, weaken tissue integrity, or rely on standard tissue structure for proper absorption can behave unpredictably or cause outsized harm.1Oxford Textbook of Medicine. Inherited defects of connective tissue: Ehlers–Danlos syndrome, Marfan’s syndrome, and pseudoxanthoma elasticum The picture is complicated further by the overlap between EDS and conditions like mast cell activation syndrome, which can make reactions to everyday medications more severe and harder to predict.
NSAIDs and the Bleeding Question
Non-steroidal anti-inflammatory drugs like ibuprofen, naproxen, and aspirin are among the most commonly flagged medications in EDS care. The concern is straightforward: NSAIDs reduce the ability of platelets to form clots, and many people with EDS already bruise easily and bleed more than expected from minor injuries because their blood vessel walls are structurally weaker. In vascular EDS especially, where arterial walls can rupture without warning, anything that impairs clotting is a serious risk. Even in the more common hypermobile type, easy bruising and prolonged bleeding from cuts or dental work are frequent complaints.
This does not mean every person with EDS must avoid ibuprofen entirely. For someone with hypermobile EDS who has no unusual bleeding history, an occasional NSAID may be reasonable with a clinician’s guidance. The risk calculus changes sharply, though, for anyone with vascular EDS or a personal history of gastrointestinal bleeding, heavy bruising, or heavy menstrual periods. Acetaminophen is often suggested as a lower-risk alternative for pain, though it does nothing for inflammation. COX-2 selective inhibitors like celecoxib affect platelet function less than traditional NSAIDs, and some specialists prefer them when anti-inflammatory treatment is genuinely needed, but they carry their own cardiovascular cautions.
Systemic Corticosteroids and Wound Healing
Oral or injected corticosteroids like prednisone and methylprednisolone are prescribed for a wide range of inflammatory and autoimmune conditions. In the general population, long-term steroid use is well known to thin the skin and slow wound healing. In someone whose skin is already fragile because of defective collagen, the effect can be dramatic. A published case report describes a patient with the benign hypermobility type of EDS who had no prior history of abnormal wound healing but developed large, non-healing skin ulcers at sites of minor trauma after starting high-dose systemic corticosteroids for another condition.2PubMed. Abnormal wound healing related to high-dose systemic corticosteroid therapy in a patient with Ehlers-Danlos syndrome benign hypermobility type The combination of already-weakened connective tissue and a drug that further suppresses collagen synthesis and tissue repair proved to be more than the skin could handle.
Short bursts of steroids for severe allergic reactions or asthma flares are sometimes unavoidable, and a few days of prednisone is unlikely to produce the same tissue damage as weeks or months of therapy. The real danger is chronic or high-dose use. If you have EDS and a clinician suggests long-term steroid therapy for any reason, it is worth a detailed conversation about alternatives and close monitoring of skin integrity. Steroid injections into joints or tendons are also worth approaching cautiously, as the local tissue-weakening effect may be amplified in already-lax connective tissue.
Local Anesthetics That Often Fail
One of the most frustrating medication experiences for people with EDS is going to the dentist or having a minor procedure and finding that the local anesthetic simply does not work well enough. A survey-based study found that roughly nine out of ten EDS respondents recalled inadequate pain prevention during dental procedures, compared to about a third of non-EDS respondents.3PubMed Central. Resistance to local anesthesia in people with the Ehlers-Danlos Syndromes presenting for dental surgery The mechanism behind this resistance is not completely understood, but it may involve the way anesthetic agents diffuse through altered connective tissue or differences in nerve sensitivity.
Not all local anesthetics perform equally poorly. In the same study, articaine had the highest patient-reported success rate among EDS respondents at about 30%, followed by bupivacaine at 25% and mepivacaine at 22%. Lidocaine, the most commonly used agent in dental offices, was reported effective by only about 8% of EDS respondents, and procaine fared even worse at 7%.3PubMed Central. Resistance to local anesthesia in people with the Ehlers-Danlos Syndromes presenting for dental surgery If you have EDS and are scheduled for dental work or a minor surgical procedure, asking your provider about using articaine or bupivacaine instead of lidocaine is a reasonable starting point. Some practitioners also find that allowing extra time for the anesthetic to take effect, using a higher volume, or supplementing with a different block technique can help.
This is not a medication to “avoid” in the traditional sense but rather one whose expected behavior changes enough that both patients and providers need to plan around it. Going into a procedure assuming standard lidocaine will work is a setup for pain and distress.
Opioids, Mast Cells, and Allergic-Type Reactions
The relationship between EDS and opioid medications is tangled. On one hand, chronic pain is extremely common in EDS, and opioids are sometimes the only medications that offer relief when other approaches fail. On the other hand, a substantial proportion of EDS patients also experience mast cell activation syndrome, a condition in which mast cells release inflammatory chemicals too easily, causing symptoms that look like allergic reactions. One study found that about two-thirds of patients who had both postural tachycardia syndrome (a common EDS companion) and EDS also showed symptoms consistent with mast cell activation.4The Ehlers-Danlos Society. Mast Cell Disorders in Ehlers-Danlos Syndrome (for Non-experts)
Many opioids are known to trigger mast cell degranulation directly, meaning they can cause flushing, hives, nausea, drops in blood pressure, and in severe cases anaphylaxis-like episodes even when the patient is not technically allergic to the drug. Morphine and codeine are among the worst offenders. For EDS patients who also have mast cell activation issues, fentanyl, tramadol, and hydromorphone tend to be better tolerated because they trigger less mast cell activity.4The Ehlers-Danlos Society. Mast Cell Disorders in Ehlers-Danlos Syndrome (for Non-experts) This does not make those opioids safe in any general sense, but it does change which specific agents a physician might choose when opioid therapy is genuinely warranted.
If you have EDS and have ever had an unusual reaction to a pain medication, it is worth discussing mast cell activation with your doctor rather than simply having the drug listed as an allergy. The treatment approach for a mast cell reaction is different from a true allergy, and getting the right label can change your options going forward.
Muscle Relaxants and Joint Stability
Muscle relaxants like cyclobenzaprine, baclofen, and benzodiazepines (diazepam, for instance) are frequently prescribed for musculoskeletal pain and spasms. In EDS, muscle spasms are common because the muscles are often working overtime to compensate for joints that the ligaments cannot adequately stabilize. Relaxing those muscles sounds helpful for the pain, but it can remove the very muscular support that is keeping joints in place. The result can be an increase in subluxations and dislocations, which creates more pain and more instability in a frustrating cycle.
This is one of those situations where the medication treats the symptom while worsening the underlying problem. Benzodiazepines carry the additional concern of being habit-forming, and their sedating effects can increase the risk of falls in someone whose joints are already prone to giving way. Some EDS patients find low-dose muscle relaxants helpful for acute flares, particularly at night when subluxation risk is somewhat lower, but as a daily maintenance strategy they are generally counterproductive. Physical therapy aimed at strengthening the muscles around hypermobile joints tends to address the root issue more effectively than medication that further loosens the system.
Fluoroquinolone Antibiotics
Fluoroquinolone antibiotics, including ciprofloxacin, levofloxacin, and moxifloxacin, carry a well-documented risk of tendon damage, including tendon rupture. Regulatory agencies have added strong warnings about this risk, particularly for older adults, those taking corticosteroids simultaneously, and those with kidney conditions. While there is limited research looking specifically at fluoroquinolone use in EDS populations, the theoretical concern is clear: if the drug damages tendons in people with normal connective tissue, the risk is plausibly higher in people whose tendons are already structurally compromised.
Many EDS-informed clinicians advise avoiding fluoroquinolones whenever a suitable alternative antibiotic exists. For urinary tract infections, skin infections, and respiratory infections, there are usually other antibiotic classes that work just as well. When a fluoroquinolone is genuinely the best or only option for a specific infection, the decision becomes a risk-benefit conversation rather than an absolute prohibition, but it should be a deliberate choice rather than a default prescription.
Cardiovascular Medications and Vascular EDS
Vascular EDS, caused by mutations affecting type III collagen, carries life-threatening risks of arterial dissection and organ rupture. Managing cardiovascular risk in these patients requires careful medication selection. A landmark trial tested celiprolol, a beta-blocker with unusual pharmacology that reduces arterial wall stress, in patients with vascular EDS. Those receiving celiprolol reached a major cardiovascular event at roughly one-third the rate of controls.5PubMed. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial This makes celiprolol one of the few medications studied specifically for vascular EDS prevention, though it is not widely available in every country and has to be accessed through special programs in some regions.
Conventional beta-blockers are sometimes prescribed for POTS-related tachycardia in hypermobile EDS, but they have not shown the same specific vascular-protective benefit seen with celiprolol in vascular EDS. Blood pressure medications that cause excessive lowering of pressure can be particularly problematic in EDS patients who already tend toward low blood pressure and orthostatic intolerance. Vasodilators, in particular, may worsen lightheadedness and fainting episodes. Any cardiovascular medication in EDS, even one that is helpful, needs to be started at a low dose and titrated carefully.
Perioperative and Anesthesia Considerations
Surgical settings bring a concentrated set of medication concerns for EDS patients. Beyond the local anesthetic resistance already discussed, general anesthesia poses its own challenges. Endotracheal intubation can be difficult in EDS patients because of cervical spine instability, jaw joint dysfunction, and the possibility of tracheal cartilage that is softer than expected.6American Journal of Case Reports. Anesthetic Management for Ehlers-Danlos Syndrome, Hypermobility Type Complicated by Local Anesthetic Allergy: A Case Report An anesthesiologist who is unaware of EDS may use standard force on a jaw that subluxates easily, or position the neck in a way that risks injury to hypermobile cervical joints.
Blood-thinning medications used during and after surgery require especially cautious dosing. Heparin and other anticoagulants administered around the time of surgery are standard for preventing blood clots, but in a patient with fragile blood vessels, the risk of post-surgical bleeding is elevated. Surgeons and anesthesiologists need to know about the EDS diagnosis before the procedure, not during it. Patients with vascular EDS face the highest surgical risk and often require vascular surgery teams even for procedures that would be routine in other patients.
Post-surgical pain management adds another layer. The combination of potential local anesthetic resistance, mast cell reactivity to certain opioids, and the desire to avoid muscle relaxants that destabilize joints means that the usual post-operative pain protocols may need significant modification. Regional nerve blocks, non-opioid adjuncts like ketamine at sub-anesthetic doses, and careful opioid selection become important conversations to have before rather than after the operation.
Gastroparesis Drugs and Autonomic Overlap
Gastrointestinal problems are extremely common in hypermobile EDS, and the link appears to run through autonomic nervous system dysfunction. The same autonomic disturbance that produces POTS can slow stomach emptying (gastroparesis) and alter motility throughout the digestive tract.7PubMed Central. An overview of Ehlers Danlos syndrome and the link between postural orthostatic tachycardia syndrome and gastrointestinal symptoms with a focus on gastroparesis Prokinetic drugs like metoclopramide and domperidone are sometimes prescribed to speed gastric emptying, but metoclopramide carries a risk of movement disorders with long-term use and can also worsen the fatigue and brain fog that many EDS patients already struggle with.
Medications that slow motility further, like anticholinergics and certain antidepressants with strong anticholinergic side effects, can make gastroparesis and constipation significantly worse. Tricyclic antidepressants such as amitriptyline are frequently used for chronic pain in EDS and do help some patients, but they tend to slow the gut. If you already have delayed gastric emptying or severe constipation, a tricyclic may solve one problem while creating another. Selective serotonin reuptake inhibitors (SSRIs) are generally better tolerated from a GI standpoint, though they can cause nausea in the early weeks.
Building a Medication Strategy With EDS
The practical difficulty for EDS patients is that so many common medications carry caveats. Pain management is a constant need, yet the most accessible painkillers all have drawbacks. The approach that most experienced EDS clinicians recommend involves layering multiple low-risk strategies rather than relying on a single drug class. Physical therapy for joint stabilization, gentle exercise programs, bracing for problem joints, and pacing of activity levels form the foundation. Medications then fill specific gaps where non-drug approaches fall short.
Keeping a personal medication diary is genuinely useful with EDS, because reactions can be idiosyncratic and specialists need that history. Noting which local anesthetics worked, which opioids caused a reaction, and which medications worsened joint instability gives future providers a roadmap that saves time and suffering. Wearing medical identification that mentions EDS is particularly important for anyone with vascular EDS, since emergency responders making split-second decisions about blood thinners, intubation, or surgical intervention need to know the diagnosis immediately.
Pharmacists are often overlooked as allies in this process. A pharmacist who understands your full medication list can flag interactions and redundancies that no single specialist may catch, especially when care is spread across rheumatology, cardiology, gastroenterology, and pain management. Because EDS-specific drug research is thin and most guidance comes from case reports, expert opinion, and extrapolation from general pharmacology, having an extra set of eyes on the prescription list is more valuable here than in conditions where large clinical trials guide every decision.